Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.324
Buy
RSI(14)
58.117
Neutral
STOCH(KDJ)(9,3,3)
63.248
Neutral
ATR(14)
3.616
Low Volatility
CCI(14)
119.126
Buy
Williams %R
28.863
Buy
TRIX(12,20)
0.196
Sell
StochRSI(14)
100.000
Overbought
Becton Dickinson and Co
BDX193.960USD
+0.100+0.05%
Close 12/05, 16:00（ET）Quotes delayed by 15 min
55.36BMarket Cap
32.99P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Becton Dickinson and Co
Currency: USD Updated: 2025-12-05Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Becton Dickinson and Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
14
analysts
Buy
Current Rating
203.751
Target Price
+5.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Becton Dickinson and Co Highlights
StrengthsRisks
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 21.84B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 71.28%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 71.28%.
Undervalued
The company’s latest PE is 33.25, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 265.27M shares, decreasing 4.08% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 4.84K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-05The company's current financial score is 8.69, which is higher than the Healthcare Equipment & Supplies industry's average of 7.45. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 5.89B, representing a year-over-year increase of 8.35%, while its net profit experienced a year-over-year increase of 23.25%.
Score
Financials
6.10
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.64
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.69
Becton Dickinson and Co's Company Valuation
Currency: USD Updated: 2025-12-05The company’s current valuation score is 7.31, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is 33.25, which is 76.11% below the recent high of 58.55 and 8.31% above the recent low of 30.49.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 7/207
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-05The company’s current earnings forecast score is 7.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.76. The average price target for Becton Dickinson and Co is 201.92, with a high of 265.34 and a low of 183.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
203.751
Target Price
+5.05%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
110
Total
7
Median
9
Average
Company name
Ratings
Analysts
Becton Dickinson and Co
BDX
14
Medtronic PLC
MDT
35
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
22
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-05The company’s current price momentum score is 9.43, which is higher than the Healthcare Equipment & Supplies industry's average of 7.40. Sideways: Currently, the stock price is trading between the resistance level at 201.97 and the support level at 180.33, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
192.716
Buy
MA10
193.067
Buy
MA20
191.074
Buy
MA50
188.103
Buy
MA100
187.991
Buy
MA200
191.251
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-05The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.40. The latest institutional shareholding proportion is 92.55%, representing a quarter-over-quarter increase of 0.21%. The largest institutional shareholder is The Vanguard, holding a total of 32.31M shares, representing 11.32% of shares outstanding, with 16.40% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
MFS Investment Management
Geode Capital Management, L.L.C.
ClearBridge Investments, LLC
1
2
Risk Assessment
Currency: USD Updated: 2025-12-05The company’s current risk assessment score is 8.98, which is higher than the Healthcare Equipment & Supplies industry's average of 4.71. The company's beta value is 0.24. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.24
VaR
+2.05%
240-Day Maximum Drawdown
+33.70%
240-Day Volatility
+29.12%
Return
Best Daily Return
60 days
+4.06%
120 days
+8.86%
5 years
+8.86%
Worst Daily Return
60 days
-2.93%
120 days
-2.93%
5 years
-18.13%
Sharpe Ratio
60 days
+0.69
120 days
+1.14
5 years
-0.03
Risk Assessment
Maximum Drawdown
240 days
+33.70%
3 years
+41.76%
5 years
+41.76%
Return-to-Drawdown Ratio
240 days
-0.40
3 years
-0.17
5 years
-0.08
Skewness
240 days
-3.31
3 years
-2.79
5 years
-1.81
Volatility
Realised Volatility
240 days
+29.12%
5 years
+23.55%
Standardised True Range
240 days
+2.29%
5 years
+2.33%
Downside Risk-Adjusted Return
120 days
+248.86%
240 days
+248.86%
Maximum Daily Upside Volatility
60 days
+15.36%
Maximum Daily Downside Volatility
60 days
+20.87%
Liquidity
Average Turnover Rate
60 days
+0.95%
120 days
+0.99%
5 years
--
Turnover Deviation
20 days
+27.42%
60 days
+46.16%
120 days
+51.44%
Peer Comparison
Healthcare Equipment & Supplies
Becton Dickinson and Co
BDX
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
CSTL
8.71 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Becton Dickinson and Co?
The TradingKey Stock Score provides a comprehensive assessment of Becton Dickinson and Co based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Becton Dickinson and Co’s performance and outlook.
How do we generate the financial health score of Becton Dickinson and Co?
To generate the financial health score of Becton Dickinson and Co, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Becton Dickinson and Co's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Becton Dickinson and Co.
How do we generate the company valuation score of Becton Dickinson and Co?
To generate the company valuation score of Becton Dickinson and Co, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Becton Dickinson and Co’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Becton Dickinson and Co’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Becton Dickinson and Co.
How do we generate the earnings forecast score of Becton Dickinson and Co?
To calculate the earnings forecast score of Becton Dickinson and Co, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Becton Dickinson and Co’s future.
How do we generate the price momentum score of Becton Dickinson and Co?
When generating the price momentum score for Becton Dickinson and Co, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Becton Dickinson and Co’s prices. A higher score indicates a more stable short-term price trend for Becton Dickinson and Co.
How do we generate the institutional confidence score of Becton Dickinson and Co?
To generate the institutional confidence score of Becton Dickinson and Co, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Becton Dickinson and Co’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Becton Dickinson and Co.
How do we generate the risk management score of Becton Dickinson and Co?
To assess the risk management score of Becton Dickinson and Co, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Becton Dickinson and Co’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Becton Dickinson and Co.
